SCHEMBL201986

SCHEMBL201986

Clc1ccc(-c2noc(CBr)n2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 2/20 0.71
NOTUM Q6P988 2/20 0.70
CYP1A2 P05177 3/20 0.60
TSHR P16473 3/20 0.59
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
POLB P06746 1/20 0.59
HTT P42858 1/20 0.59
MAPK1 P28482 3/20 0.57
ALDH1A1 P00352 2/20 0.57
CYP2D6 P10635 2/20 0.57
CYP2C19 P33261 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
IDO1 P14902 1/20 0.56
SCN5A Q14524 2/20 0.55
SCN10A Q9Y5Y9 2/20 0.55
ERCC1 P07992 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL507782 0.84 NOTUM (0.72) SIRT2NOTUMCYP1A2TSHRNPC1
SCHEMBL28869663 0.84 SIRT2 (0.71) SIRT2NOTUMTSHRNPC1RAB9A
SCHEMBL2094888 0.82 NOTUM (0.70) SIRT2NOTUMCYP1A2TSHRNPC1
SCHEMBL201607 0.82 NOTUM (0.70) SIRT2NOTUMCYP1A2TSHRNPC1
SCHEMBL7895236 0.82 NOTUM (1.00) SIRT2NOTUMCYP1A2TSHRNPC1
SCHEMBL5356293 0.82 NOTUM (1.00) SIRT2NOTUMCYP1A2TSHRNPC1
SCHEMBL18040200 0.82 NOTUM (0.70) SIRT2NOTUMCYP1A2TSHRNPC1
SCHEMBL12434474 0.82 NOTUM (0.70) SIRT2NOTUMCYP1A2TSHRNPC1
SCHEMBL8286815 0.82 NOTUM (0.70) SIRT2NOTUMCYP1A2TSHRNPC1
SCHEMBL10173253 0.82 SMN1; SMN2 (0.59) TSHRNPC1RAB9ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115093377-B Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2023-04-07 CN claimed
CN-115093377-A Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2022-09-23 CN claimed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
CN-115093377-B Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2023-04-07 CN disclosed
CN-115093377-A Haloalkyl-containing 1,2, 4-oxadiazole derivative and preparation method and application thereof 贵州大学 2022-09-23 CN disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 EP disclosed
CN-102008459-A Antibacterial agents PROLYSIS LTD 2011-04-13 CN disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
CN-101404989-A Antibacterial agent PROLYSIS LTD (GB) 2009-04-08 CN disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 EP disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 SIRT2 2868/4885NOTUM 4321/4885CYP1A2 537/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 SIRT2 2237/4885NOTUM 3566/4885CYP1A2 383/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 SIRT2 2237/4885NOTUM 3566/4885CYP1A2 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.